Home Cart Sign in  
Chemical Structure| 188181-42-2 Chemical Structure| 188181-42-2

Structure of Elacytarabine
CAS No.: 188181-42-2

Chemical Structure| 188181-42-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CP 4055 (Elacytarabine) is a lipid-conjugated derivative of the nucleoside analog cytarabine. CP 4055 is an antineoplastic drug with cytotoxicity in solid tumors.

Synonyms: CP-4055; CP 4055

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Elacytarabine

CAS No. :188181-42-2
Formula : C27H45N3O6
M.W : 507.66
SMILES Code : O=C(CCCCCCC/C=C\CCCCCCCC)OC[C@H]([C@@H](O)[C@@H]1O)O[C@H]1N2C=CC(N)=NC2=O
Synonyms :
CP-4055; CP 4055
MDL No. :MFCD19443751
InChI Key :FLFGNMFWNBOBGE-FNNZEKJRSA-N
Pubchem ID :6438895

Safety of Elacytarabine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Elacytarabine

DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00232726 Malignant Melanoma ... More >> Neoplasm Metastasis Less << Phase 2 Completed - United States, Pennsylvania ... More >> University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213-2584 Norway The Norwegian Radium Hospital Oslo, Norway, NO-0310 Sweden University Hospital Lund, Sweden, SE-221 85 Less <<
NCT01147939 Acute Myeloid Leukemia (AML) Phase 3 Completed - -
NCT00498836 Malignant Melanoma Phase 2 Completed - United States, Pennsylvania ... More >> University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Texas Cancer Therapy and Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 Norway The Norwegian Radium Hospital Oslo, Norway, NO-0310 Sweden Lund University Hospital Lund, Sweden, SE-221 85 Umeå University Hospital Umeå, Sweden Uppsala University Hospital Uppsala, Sweden, SE-751 85 Less <<
NCT01035502 Acute Myeloid Leukemia Phase 2 Completed - United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 France CHU Lyon, Hospital Edouard Herriot Lyon, France, 69437 Institut Paoli-Calmettes Marseille, France, 13273 CHU Toulouse, Hospital Purpan Toulouse, France, 31059 Germany Charite University Hospital Benjamin Franklin Berlin, Germany, 12200 Universitätsklinikum Münster Münster, Germany Universitätsklinikum Ulm Ulm, Germany, D-89081 Norway Haukeland University Hospital Bergen, Norway Less <<
NCT01783964 Not Applicable as This is a Ma... More >>ss Balance/Pharmacokinetic Study Performed in Healthy Subjects Less << Phase 1 Completed - United Kingdom ... More >> Quotient Clinical Ruddington, Nottngham, United Kingdom, NG11 6JS Less <<
NCT00498407 Advanced Colorectal Cancer|Col... More >>orectal Cancer Less << PHASE2 COMPLETED 2025-12-08 Aberdeen Royal Infirmary, Fore... More >>sterhill,, Aberdeen, AB25 2ZN, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Medical Oncology Dept. of Cancer Studies and Molecular Medicine, Leicester Royal Infirmary, Leicester, LEI 5WW, United Kingdom|Macmillan Lead Clinician in Gastro-intestinal Cancer Mount Vernon Cancer Centre, Northwood, HA6 2RN, United Kingdom Less <<
NCT00831636 Ovarian Cancer Phase 1 Phase 2 Completed - Belgium ... More >> U.Z. Gasthuisberg, Gynecologic Oncology, Herestraat 49 Leuven, Belgium, B-3000 Italy Medical Oncology C, National Cancer Institute, Centro di Riferimento Oncologico Aviano (PN), Italy Medical Oncology B, National Cancer Institute, Via Mariano Semmola Naples, Italy, IT-80131 Department of Oncology, Catholic University of the Sacred Heart Rome, Italy, 00168 Medical Oncology, Fatebenefratelli Hospital, Isola Tiberina Rome, Italy Less <<
NCT01258816 Relapsed/Refractory AML Phase 1 Completed - Spain ... More >> ICO - Hospital Duran i Reynals Barcelona, Catalunya, Spain, 08907 Hospital General de la Vall d' Hebron Barcelona, Spain, 08035 Hospital San Pedro Alcantara Cáceres, Spain, 10003 United Kingdom Brighton & Sussex University Hospitals NHS Trust Brighton, United Kingdom, BN2 5BE University Hospital of Wales, Cardiff Cardiff, United Kingdom, CF14 4XW St Bartholomew's Hospital London, United Kingdom, EC1A 7BE Less <<
NCT00405743 Hematologic Malignancies ... More >> AML Less << Phase 1 Phase 2 Completed - United States, New York ... More >> Mew York Medical College, Division of Oncology Valhalla, New York, United States, 10595 United States, North Carolina Duke University Medical Center (DUMC) Durham, North Carolina, United States, 27710 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. San Antonio, Texas, United States, 78229 France Hematology Service, Hôpital Beaujon and Hôpital Avicenne Bobigny, Paris, France, 93009 Centre Hospitalier Universitaire, CHU de Lyon, Service d'Hematologie Clinique Lyon, France, 69437 Institut Paoli-Calmettes Marseille, France, 13273 Centre Hospitalier Universitaire CHU de Toulouse, Hopital Purpan Toulouse, France, 40031-31059 Germany University Hospital Benjamin Franklin Med.Clinic III Berlin, Germany, 12200 Department of Internal Medicine Klinikum der Johann Wolfgang Goethe-Universität Medizinische Klinik II Frankfurt am Main, Germany, 60590 Westfälische Wilhelms-Universität Münster Medizinische Klinik und Polikinik Innere Medizin A Münster, Germany, 48129 Italy Institute of Hematology & Medical Oncology L and A Serágnoli University of Bologna Bologna, Italy, 40138 Universitá degli Studi di Roma Ematologia- Policlinico Tor Vergata Rome, Italy, 00133 Norway Department of Hematology, Ullevål University Hospital, University of Oslo Oslo, Norway, 0407 United Kingdom Christie Hospital Manchester, United Kingdom, M20 4BX Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.85mL

1.97mL

0.98mL

19.70mL

3.94mL

1.97mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories